Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT06272955 Enrolling by invitation - Parkinson Disease Clinical Trials

LONG TERM EFFECTS OF SPINAL CORD STIMULATION

SCS for FOG OL
Start date: January 4, 2024
Phase:
Study type: Observational [Patient Registry]

Parkinson Disease (PD) patients experience a variety of motor issues such as walking difficulties, loss of balance, and freezing while walking, which impacts their quality of life. Some symptoms, like freezing of gait (FOG), do not respond to medications typically used to treat PD. Current surgical procedures used to alleviate PD symptoms also do not always improve FOG. Since many traditional therapies have failed for the treatment of FOG, researchers have proposed the use of newer treatments. Recent research in animal models and clinical human data using Spinal Cord Stimulation (SCS) has produced promising results, specifically showing improvement in FOG with the use of SCS in patients with PD. The purpose of this study is to explore the long-term motor and non-motor effects of SCS in PD patients after completing participation on H-49023. The investigators hypothesize that SCS significantly decreases FOG episodes in patients with PD. 1. Assess the long-term safety, tolerability and preliminary evidence of effectiveness of upper thoracic spinal cord stimulation for freezing of gait in Parkinson's (PD) patients. 2. Allowing patients to choose between the two SCS programming paradigms based on their motor, nonmotor and quality of life measures in PD patients with freezing of gait.

NCT ID: NCT06272838 Recruiting - Parkinson Disease Clinical Trials

Biodex Balance System in Patients With Parkinson's Disease

Start date: February 28, 2024
Phase: N/A
Study type: Interventional

Conventional balance exercises are an effective rehabilitation method applied in routine rehabilitation programs for Parkinson's patients. With technological developments, balance exercises

NCT ID: NCT06272448 Recruiting - Parkinson Disease Clinical Trials

teleRehabilitation for pAtients With ParkInson's Disease at Any mOment

RAPIDO
Start date: November 15, 2022
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to test the feasibility and safety of a telerehabilitation and telemonitoring approach in people with Parkinson's disease at any stage. The main questions it aims to answer are: will patients with Parkinson's disease comply with the recommended level of training at home using an ad hoc developed telerehabilitation platform? • Will this training be safe and impact the patient's well-being perception? Participants will be given a tablet and instructed to access an online platform to observe different motor tasks presented in as many video clips by experienced therapists.They will be requested to perform the motor tasks per a predetermined protocol over 3 months. Their compliance with the recommended training will be checked by physiotherapists every 15 days during phone calls, whereas their daily level of motor activity will be recorded by a smartwatch.

NCT ID: NCT06264037 Recruiting - Stroke Clinical Trials

The Experience in Neurorehabilitation Setting: a Qualitative Study

NURSEXPERIENCE
Start date: March 15, 2023
Phase:
Study type: Observational [Patient Registry]

In this exploratory qualitative study with a hermeneutic phenomenological approach, we will describe and understand the experience of treatment and hospitalization in hospitalized people suffering from stroke, multiple sclerosis, Parkinson's disease and patients post-neurosurgery for oncological causes. Patients will be interviewed in a semi-structured manner and sampling will take place for each of the pathology groups according to the saturation method.

NCT ID: NCT06263673 Recruiting - Parkinson Disease Clinical Trials

Anti-Diabetic Medications to Fight PD and LBD

Start date: May 7, 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.

NCT ID: NCT06263010 Recruiting - Parkinson Disease Clinical Trials

Allopregnanolone as a Regenerative Treatment for Parkinson's Disease

Allo-PD
Start date: January 12, 2024
Phase: Phase 1
Study type: Interventional

The goal of this open-label, pilot clinical trial is to test allopregnanolone as a regenerative treatment in patients with Parkinson's disease (PD). The main questions this study aims to answer are: 1. Is a large-scale clinical trial testing how well it works in patients with PD feasible? 2. Is allopregnanolone safe and well-tolerated in patients with PD. 3. Can we see any signals of changes in imaging and clinical scales? Participants will receive a weekly infusion in their vein of allopregnanolone for a total of 12 weeks. There is no placebo so everyone receives allopregnanolone and "Open-label" means the study is not blinded so both the participant and investigators know the assigned treatment.

NCT ID: NCT06260384 Recruiting - Arrythmias Clinical Trials

Wolf-Parkinson-White Syndrome and Asymptomatic Pre-excitation in Africa (a Multicenter WPW African Registry)

Start date: May 1, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this prospective observational study is to characterize the clinical profile of patients with WPW syndrome and patients with asymptomatic WPW pattern on ECG in different African countries and how these patients are managed across Africa Participants would include many different ethnicities at centers where the number of cardiac patients treated is high. All patients attending outpatient cardiology clinics or referred to Cath Lab for electrophysiological studies who are diagnosed to have a Wolf-Parkinson white pattern on the ECG are either symptomatic or asymptomatic. All patients fulfilling the eligibility criteria will be approached by the research team and asked if they wish to take part in the study. The exclusion criteria will be any participant who does not consent to the study. A baseline cardiovascular history (including hypertension, diabetes, heart failure, coronary artery disease, hyperlipidemia, smoking, valve disease, and arrhythmia) will be recorded. A detailed history will be taken about symptoms, medications and presence of family history of similar cases or sudden cardiac death 12-lead ECG will be recorded to confirm the presence of pre-excitation and determine the localization of the accessory pathway using the modified Aruda algorithm. This will be done by two of the research teams in each center. Then other data from the electrophysiological study and ablation will be filled in by the research team from the data systems of each center.

NCT ID: NCT06260228 Recruiting - Parkinson Disease Clinical Trials

HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH)-Parkinson's Disease (HOBSCOTCH-Parkinson's)

HOBSCOTCH-PD
Start date: January 5, 2024
Phase: N/A
Study type: Interventional

The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Parkinson's Disease (PD) The main questions it aims to answer are: 1. Can the current HOBSCOTCH program be adapted for people with PD? 2. Will people with PD experience improved quality of life similar to that found in people with epilepsy after participating in the HOBSCOTCH program? Participants will be asked to: - attend nine, one-hour virtual (online and/or by telephone) HOBSCOTCH-PD sessions with a one-on-one certified HOBSCOTCH-PD coach - complete a brief clinical questionnaire about their diagnosis of PD - complete two questionnaires before and after the HOBSCOTCH-PD sessions about their quality of life and about memory and thinking processes - keep a short daily diary about their PD symptoms and use of the self-management strategies taught in the HOBSCOTCH-PD program - complete a brief Satisfaction Survey after the entire HOBSCOTCH-PD program

NCT ID: NCT06259708 Not yet recruiting - Parkinson Disease Clinical Trials

Using Low Intensity Focused Ultrasound to Modulate Deep Brain Areas for Tremor Control in Parkinson's Disease Patients.

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

Researchers have found that a treatment called Magnetic Resonance guided Focused Ultrasound (MRgFUS) can effectively reduce tremors in patients with essential tremor (ET) and Parkinson's disease (PD). They noticed that ET patients initially responded better to the treatment than PD patients, but by the end of the treatment, both groups showed similar improvement. The study also suggested that targeting a specific area of the brain called the Zona Incerta (ZI) may be more beneficial for PD patients. Based on these findings, the investigators plan to use low-intensity focused ultrasound to directly modulate the ZI area and investigate the mechanisms of reduced tremors in PD patients. The investigators will also compare the effectiveness of this approach with the current target, the ventral intermediate nucleus (Vim) of the thalamus. The investigators will use a simulation model to determine the best ultrasound parameters for this new approach and will also examine the impact of the treatment on the brain's network activity using functional Magnetic Resonance Imaging. Success of this project may lay the foundation for finding a more effective target for MRgFUS treatment of PD tremor.

NCT ID: NCT06256835 Not yet recruiting - Parkinson Disease Clinical Trials

Effect of Myofascial Release on Dysphagia in Parkinson's Patients

Start date: April 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore Clinical Effect of Myofascial Release Therapy in Dysphagic Parkinson's Patients. The main question it aims to answer is: • Can Myofascial Release Therapy improve swallowing function in Parkinson's Patients? Patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given Myofascial Release Therapy. The study lasts 21 days for each patient. Researchers will compare the Functional Oral Intake Scale, Penetration-Aspiration Scale, Swallowing Quality of Life to see if the Myofascial Release Therapy can help improve the situation.